The report "IVD Quality Control Market by Source (Plasma, Whole Blood, Urine), Technology (Immunoassay, Hematology, Microbiology, Coagulation), Manufacturer (Third party, OEM), End Users (Hospitals, Lab, Research) - Global Forecast to 2027", is projected to reach USD 1.6 billion by 2027 from USD 1.3 billion in 2022, at a CAGR of 5.4% during the forecast period.

the global IVD Quality Control Market is projected to reach USD 1.4 billion by 2026 from USD 1.1 billion in 2021, at a CAGR of 5.3% during the forecast period.

Browse in-depth TOC on "In Vitro Diagnostics (IVD) Quality Control Market"
252 – Tables
59 – Figures
342 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582

The IVD testing plays a significant role in clinical decision-making. Over the years, IVD quality control products and procedures have become mandatory in accredited clinical or medical laboratories. The applications of IVD quality control products have also widened over the years, with a number of quality controls currently available in the market for clinical chemistry, immunochemistry, hematology, molecular diagnostics, coagulation, and microbiology. To ensure technological competitiveness, companies are continuously launching innovative and advanced quality control products in the market for a variety of applications.

The growth of the In Vitro Diagnostics Quality Control Market is primarily driven by the rising number of accredited clinical laboratories, rising geriatric population, rising demand for external quality assessment programs, increasing adoption of and POC instruments in developed regions and increasing adoption of third-party quality controls. The rising focus on multi-analyte controls is also expected to offer significant growth opportunities for the market in the coming years. The use of quality control products is, however, not mandatory for all clinical laboratories in many countries. The lack of regulations for these products is expected to adversely affect market growth.

The product & service segment holds the highest share of the total IVD quality control market during the forecast period.

Based on product & service, the In Vitro Diagnostics Quality Control Market is segmented into quality control products, data management solutions, and quality assurance services. The quality control products segment accounted for the largest share of the market in 2020. The increasing number of accredited laboratories and mandates for the use of quality controls from regulatory bodies to ensure the accuracy of diagnostic test results are driving the growth of the IVD quality control products market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=198032582

Immunochemistry accounted for the highest share of the technology segment of the global IVD quality control market

Based on technology, the In Vitro Diagnostics Quality Control Market is broadly segmented into clinical chemistry, immunochemistry, hematology, coagulation & hemostasis, microbiology, molecular diagnostics, and other technologies. The immunochemistry segment accounted for the largest share of the market in 2020. The large share of this segment can be attributed to the increasing use of multi-analyte controls to perform immunoassay tests in laboratories. The use of immunoassay tests in clinical laboratories has also increased due to the high sensitivity of these tests over conventional methods.

Third-party controls accounted for the largest share for the IVD quality control market

Based on manufacturer, the In Vitro Diagnostics Quality Control Market is segmented into third-party controls and OEM controls. The third-party controls segment accounted for the largest share of the global market in 2020. The large share of this segment can be attributed to the increasing use of third-party quality controls across the globe to verify the accuracy and reliability of tests

Hospitals accounted for the highest share of the global IVD quality control market

The key end users of IVD quality controls studied in this report include hospitals, clinical laboratories, research & academic institutes, and other end users. The hospitals segment accounted for the largest share of the market in 2020, owing to the large volume of diagnostic tests carried out in hospitals.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=198032582

North America is expected to account for the largest share for players operating in the global IVD quality control market

Geographically, the global In Vitro Diagnostics Quality Control Market studied in this report is divided into five major regions— North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global market, followed by Europe. Recommendations for and approvals of quality control products from the FDA and the College of American Pathologists (CAP) and the presence of well-established distribution channels and leading companies in the US are driving the market in North America.

Some of the key players in the In Vitro Diagnostics (IVD) Quality Control Market include Bio-Rad Laboratories, Inc. (US), Randox Laboratories Ltd. (UK), Thermo Fisher Scientific, Inc. (US), LGC Limited (UK), and Abbott Laboratories (US). Other prominent payers in the market include Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Fortress Diagnostics (UK), SERO AS (US), Sysmex Corporation (Japan), Ortho-Clinical Diagnostics (US), Helena Laboratories Corporation (US), Quidel Corporation (US), Sun Diagnostics, LLC (US), Seegene Inc. (South Korea), ZeptoMetrix Corporation (US), Qnostics (UK), Bio-Techne Corporation (US), Microbiologics (US), Microbix Biosystems (Canada), Streck, Inc. (US), Alpha-Tec Systems (US), Maine Molecular Quality Controls, Inc. (US), and Grifols, S.A. (Spain). These players aim to secure higher market shares through strategies such as product launches, expansions, agreements, and acquisitions.

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/in-vitro-diagnostics-quality-controls-market.asp 
Visit Our Web Site: https://www.marketsandmarkets.com 
Content Source:  https://www.marketsandmarkets.com/PressReleases/in-vitro-diagnostics-quality-controls.asp